How is GLOW dosed, mixed and read in syringe units?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mg
    mg
    mg

    Filled in from the blend in the Milligram app's catalogue (10 mg + 10 mg + 50 mg). Change them to match your vial.

    mL
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds GLOW and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    No label or human trial of GLOW gives a dose; a vendor lists the vial as 70 mg in all, and of people logging GLOW in Milligram, 18% set up 1 mg and 12% set up 3.5 mg.113

    The guide's example

    1,000 mcg of GLOW from a 70 mg vial mixed with 2 mL is 2.9 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water3 mL of water
    70 mg70 mg/mL: 1,000 mcg is 1.4 units, 3,500 mcg is 5 units35 mg/mL: 1,000 mcg is 2.9 units, 3,500 mcg is 10 units23.333 mg/mL: 1,000 mcg is 4.3 units, 3,500 mcg is 15 units

    Vial, water and syringe units

    A vendor page (ENOS Labs USA, a research-use listing) lists GLOW as one vial of BPC-157 10 mg, TB-500 10 mg and GHK-Cu 50 mg, 70 mg in all.1

    Among people logging GLOW, 84% set up doses in mg and 9% in IU.13 Of the same people, 18% set up 1 mg and 12% set up 3.5 mg; the worked example below is 1 mg.13

    No maker's leaflet or label gives a water volume for a GLOW vial, so the table shows a range of volumes. The bacteriostatic water label says the volume of diluent depends on the drug maker's recommendation.2

    1,000 mcg of GLOW from a 70 mg vial mixed with 2 mL is 2.9 units on a U-100 syringe.

    The calculator is at the top of the page

    What labels and trials give for GLOW and its parts

    The pack's DailyMed search found no label for GLOW, BPC-157 or TB-500. An FDA page on compounding lists BPC-157 among bulk substances previously in category 2 (substances that may present significant safety risks) and withdrawn by their nominators, and says compounded BPC-157 may pose risk for immunogenicity for certain routes of administration.3 No label or human trial of the blend gives a schedule or cycle length. For GHK-Cu, the FDA page says human data on the injectable are limited.3

    The pack's search found no human trial of the blend, so these are trials of single parts.

    TrialDose and schedulePeopleLength
    Lee and Burgess 2025, BPC-157 intravenous pilot10 mg on day 1 and 20 mg on day 2, each in 250 cc of saline over one hour2 healthy adultsDays 1 and 2 4
    Ruff 2010, thymosin beta 4 phase I (not TB-500)Intravenous single dose of placebo or 42, 140, 420 or 1260 mg, then the same dose dailyFour cohorts of ten healthy subjects14 days 5
    Wang 2021, recombinant thymosin β4 phase I (not TB-500)Intravenous; single doses of 0.05 to 25.0 μg/kg or placebo; multiple-dose part 0.5, 2.0 or 5.0 μg/kg54 healthy subjects (single-dose), 30 (multiple-dose)One dose (single-dose part); daily for 10 days (multiple-dose part); both observed for 28 days 6

    The pilot by Lee and Burgess (2025) reported no adverse effects in 2 healthy adults at up to 20 mg, by the intravenous route and not under the skin.4

    Registered trials, reviews and the vendor listing

    Registry entryDose and schedulePeopleLength
    BPC-157 phase 1, NCT02637284Oral 1 mg tablets of BPC-157 or placebo: a single dose of 1, 3 or 6 tablets in phase 1a; three tablets every 8 hours in phase 1bTwelve subjects per single-dose arm in phase 1a; 36 on BPC-157 and 6 on placebo in phase 1b; 42 enrolledSingle dose (phase 1a); 2 weeks (phase 1b) 7
    BPC-157 phase 2, NCT07437547 (recruiting)Subcutaneous BPC-157 or placebo (1:1), once daily, dose in mg not stated120 enrolled, with an acute MRI-confirmed grade II hamstring strain14 days 8
    TB-500 phase 1/2, NCT07487363 (recruiting)Low, medium and high dose cohorts, each randomized 3:1 against placebo; dose levels not in the public entry80 enrolled, adults with stable atherosclerotic cardiovascular disease8-week dosing period, then a 4-week safety follow-up 9

    A review says BPC-157 has no approved formulation, no validated dosing regimen and no completed Phase II trial.10 For GHK-Cu, a 2026 systematic review calls the human evidence a handful of small trials and series, mostly at the cosmetic-cream level; in one it describes, Huh and Koch (2006), thirteen patients after CO2 laser resurfacing were randomized to a GHK-Cu cream and lotion or a petrolatum-based regimen, and the objective endpoints were null.11

    Storage before and after mixing

    The pack found no storage temperature or time for GLOW before or after mixing. The bacteriostatic water label says to store the water at 20 to 25°C (68 to 77°F).2 It says not to store reconstituted solutions unless the drug's maker directs otherwise.2

    Frequently asked questions

    Which route do people log for GLOW?

    Of people logging GLOW, 94% logged the route as under the skin.13

    Does the vendor say GLOW is for human use?

    The vendor page says the product is not for human administration.1

    Is the content of a commercial GLOW vial checked?

    A 2026 review of BPC-157, thymosin beta-4 and TB-500 says commercial products raise concerns regarding identity, purity, concentration, sterility and manufacturing consistency.12

    How the logged figures are counted

    Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

    References

    1. Enos USA (vendor product page). GLOW Blend 70MG Research Peptide Blend | ENOS Labs USA. enoslabsusa.com
    2. Henry Schein, Inc. via DailyMed (US label). Bacteriostatic Water Injection, USP 30 mL Multi Dose Vial. 2026. dailymed.nlm.nih.gov
    3. FDA. Substances in Compounding that May Present Significant Safety Risks. fda.gov
    4. PubMed. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. 2025. pubmed.ncbi.nlm.nih.gov
    5. PubMed. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. 2010. pubmed.ncbi.nlm.nih.gov
    6. PubMed. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. 2021. pubmed.ncbi.nlm.nih.gov
    7. ClinicalTrials.gov. NCT02637284: PCO-02 - Safety and Pharmacokinetics Trial. 2016. clinicaltrials.gov
    8. ClinicalTrials.gov. NCT07437547: BPC 157 for Acute Hamstring Muscle Strain Repair. 2028. clinicaltrials.gov
    9. ClinicalTrials.gov. NCT07487363: TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. 2028. clinicaltrials.gov
    10. PubMed. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. 2026. pubmed.ncbi.nlm.nih.gov
    11. PMC. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. 2026. pmc.ncbi.nlm.nih.gov
    12. PubMed. Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. 2026. pubmed.ncbi.nlm.nih.gov
    13. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted